Abstract
Abstract Carfilzomib is a newer class of selective proteasome inhibitor approved by FDA in 2012. It is used for the treatment of refractory multiple myeloma in patients who have received two prior therapies. We report a case of drug induced thrombotic microangiopathy associated with carfilzomib in a patient with refractory multiple myeloma. <span style=mso-bidi-font-size: 10.0pt;font-family: times= new= roman,serif;color:black;mso-themecolor:text1=>Keywords: Carfilzomib; Proteasome inhibitor; Thrombotic microangiopathy; Refractory <span style=font-size:11.0pt; mso-bidi-font-size:10.0pt;line-height:107%;font-family: times= new= roman,serif;= mso-fareast-font-family:calibri;mso-fareast-theme-font:minor-latin;color:black;= mso-themecolor:text1;mso-ansi-language:en-us;mso-fareast-language:en-us;= mso-bidi-language:ar-sa=>Abbreviations: <span style=font-size:10.0pt; line-height:107%;font-family: times= new= roman,serif;mso-fareast-font-family:= calibri;mso-fareast-theme-font:minor-latin;color:black;mso-themecolor:text1;= mso-ansi-language:en-us;mso-fareast-language:en-us;mso-bidi-language:ar-sa=> AKI: Acute Kidney Injury; TMA: Thrombotic Microangiopathy; LDH: Lactate Dehydrogenase; CKD: Chronic Kidney Disease; RA: Rheumatoid Arthritis; TTP: Thrombotic Thrombocytopenic Purpura; HUS: Hemolytic Uremic Syndrome
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
